The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 18, 2011
Filed:
Dec. 17, 2007
Compositions and methods for the identification, assessment, prevention and therapy of human cancers
Edwin Clark, Ashland, MA (US);
Tallessyn Grenfell-lee, Cambridge, MA (US);
Karen LU, Houston, TX (US);
Lynn Hartmann, Rochester, MN (US);
Jeffrey L. Brown, Arlington, MA (US);
Robert C. Bast, Jr., Houston, TX (US);
Gordon B. Mills, Houston, TX (US);
Edwin Clark, Ashland, MA (US);
Tallessyn Grenfell-Lee, Cambridge, MA (US);
Karen Lu, Houston, TX (US);
Lynn Hartmann, Rochester, MN (US);
Jeffrey L. Brown, Arlington, MA (US);
Robert C. Bast, Jr., Houston, TX (US);
Gordon B. Mills, Houston, TX (US);
Millennium Pharmaceuticals, Inc, Cambridge, MA (US);
Mayo Foundation for Medical Edication and Research, Rochester, MN (US);
Board of Regents, The University of Texas System, Austin, TX (US);
Abstract
The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of 'sensitivity markers.' These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of 'resistance markers.' These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.